Dallas, TX -- (SBWIRE) -- 01/31/2012 -- Immunosuppressants generated revenues of $92.2 billion in 2010 while immunostimulants generated revenues of $53.7 billion. There are more classes of immunosuppressants than immunostimulants because it is difficult to boost the cells of the immune system as they all respond to antigens in different ways. The immunostimulants market is estimated to grow at a Compound Annual Growth Rate (CAGR) of 10.5% and the immunosuppressants market is forecast to grow at a CAGR of 7.3%, although there are more products in the pipeline for immunosuppressants. Immunostimulatory Monoclonal Antibodies (mAbs) such as cancer antibodies and vaccines will contribute most to the growth of the markets as there is a great deal of scope for these classes in the oncology market, valued at $60.5 billion in 2010.

Antimetabolic Drugs Generated the Highest Revenues of all Classes of Immunomodulators

Antiproliferative and antimetabolic drugs generated revenues of approximately $33.2 billion in 2010. However, with the gradual approval of mAbs as first-line treatment, antiproliferative and antimetabolic drugs will grow at a comparatively slow rate. Conventional therapy, namely chemotherapy, has a long history of poor safety profiles due to systemic action characteristics, which means its often fails to impart the desired effect at the site of action. Cancer is better managed with personalized oncological treatments such as measuring erbB2 (erythroblastic leukemia viral oncogene homolog 2) and EGFR (Epidermal Growth Factor Receptor) proteins in breast, lung and colorectal cancer patients before selecting suitable treatments. Herceptin is used in the treatment of women with breast cancer in which HER2 (Human Epidermal growth factor Receptor 2) protein is overexpressed.

Antibodies Market Forecast to show Highest Growth Rate of all Classes of Immunomodulators

Antibodies were the fastest growing segment in the global immunomodulators market in 2010. The global antibodies market was worth $51.8 billion in 2010, comprising mAbs and fusion proteins. Antibodies are used in a range of oncology indications and autoimmune diseases. In 2010, immunostimulating antibodies generated revenues of $23 billion while immunosuppressive antibodies generated $28.8 billion. MAbs are gradually moving into the treatment of Central Nervous System (CNS) disorders such as Alzheimer’s disease and metabolic disorders such as diabetes. The first therapeutic mAb approved by the Food and Drug Administration (FDA) was Muromonab-CD3 (trade name Orthoclone OKT3), a murine IgG2a CD3 specific transplant rejection drug, also known as muromonab. It was approved in 1986 and was used in steroid-resistant solid organ transplant recipients. Since the launch of Orthoclone OKT3 in 1992, 30 mAbs have been launched globally. Of these, three have been discontinued due to safety issues. Successful mAbs such as rituxan, avastin and remicade have received regulatory approvals for multiple indications, further increasing the patient base.

Visit http://www.reportsnreports.com/reports/145417-immunomodulators-market-to-2017-immunosuppressant-antibodies-to-replace-antimetabolites-as-the-highest-value-sector-by-2017.html or contact sales@reportsandreports.com for complete report.